Get started
Author

Amy Lauren Cummings

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
2018 · A. Lisberg, A. Cummings, et al. · Journal of Thoracic Oncology · 578
PDF
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
2023 · Marcelo V. Negrao, Haniel A. Araujo, et al. · Cancer Discovery · 200
PDF
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
2024 · Ferdinandos Skoulidis, Haniel A. Araujo, et al. · Nature · 186
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
2023 · Jay M. Lee, Ciaran J. McNamee, et al. · Journal of Thoracic Oncology · 83
PDF
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
2019 · Siwen Hu-Lieskovan, Aaron Lisberg, et al. · Clinical Cancer Research · 72
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
2018 · Izak Faiena, Amy L Cummings, et al. · Drug Design Development and Therapy · 48
PDF
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
2020 · Amy L. Cummings, Jaklin Gukasyan, et al. · Nature Cancer · 44
Consent document translation expense hinders inclusive clinical trial enrolment
2023 · Maria A. Velez, Beth A. Glenn, et al. · Nature · 36
PDF
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
2018 · Charlene M. Fares, Timothy J. Williamson, et al. · JCO Clinical Cancer Informatics · 27
Targeted Therapy for Non-Small Cell Lung Cancer
2020 · Zorawar S. Noor, Amy L. Cummings, et al. · Seminars in Respiratory and Critical Care Medicine · 26
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
2021 · Edward B. Garon, Alexander I. Spira, et al. · Clinical Cancer Research · 25
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
2022 · Jonathan W. Goldman, Amy Lauren Cummings, et al. · Journal of Clinical Oncology · 18
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
2021 · Nanruoyi Zhou, Maria A Velez, et al. · Lung Cancer · 17
PDF
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
2022 · Yinjie Gao, Michelle M. Stein, et al. · Cancer Immunology Immunotherapy · 13
PDF
Thyroid Carcinoma Metastases to Axillary Lymph Nodes: Report of Two Rare Cases of Papillary and Medullary Thyroid Carcinoma and Literature Review
2013 · Amy L. Cummings, Melanie Goldfarb · Endocrine Practice · 13
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
2022 · David J. Benjamin, Shuai Chen, et al. · JTO Clinical and Research Reports · 12
PDF
Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone.
2022 · Jackson Michuda, Ben Ho Park, et al. · Journal of Clinical Oncology · 11
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
2023 · Clayton P. Smith, Michael Xiang, et al. · JTO Clinical and Research Reports · 9
KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
2019 · Amy Lauren Cummings, Kate M. Santoso, et al. · Translational Lung Cancer Research · 8
PDF
A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.
2018 · Aaron Elliott Lisberg, Amy Lauren Cummings, et al. · Journal of Clinical Oncology · 7
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
2025 · Jay M. Lee, Alessandro Brunelli, et al. · JTO Clinical and Research Reports · 5
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
2017 · A. Lisberg, J. Hunt, et al. · Journal of Thoracic Oncology · 5
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
2025 · Jay M. Lee, Jean-Louis Pujol, et al. · JTO Clinical and Research Reports · 4
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study.
2025 · Samer Alkassis, Marla Lipsyc-Sharf, et al. · Journal of Clinical Oncology · 4
PDF
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients
2025 · Michael S. Oh, Edward B. Garon, et al. · Clinical Lung Cancer · 4
PDF
Works count: 203
Citation count: 1,491
H-index: 13
I10-index: 17
Year
Topic
Type